Notably, DT-216, a PIP that facilitates the transcription of repressive GAA repeats to enhance frataxin expression in Friedreich’s ataxia, is currently undergoing phase I clinical trials (NCT05285540) (66). The gene discussed is FXN; the disease is Friedreich ataxia.